Top 70+ Pharmaceutical Companies In North Carolina In 2021
← Visit blog

Top 70+ Pharmaceutical Companies In North Carolina In 2021

Updated on March 11th, 2021

Top 70+ Pharmaceutical Companies In North Carolina In 2021

A hand curated list of 70+ top pharmaceutical companies in North Carolina.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Salix Pharmaceuticals ($500M to $1B)
  2. Sisu Pharma ($1M to $10M)
  3. Arrevus (Less than $1M)
  4. EternaTear (Less than $1M)
  5. Exodos Life Science Partners ($1M to $10M)
  6. NovaTarg Therapeutics (Less than $1M)
  7. CertiRx ($10M to $50M)
  8. Charter Medical (Less than $1M)
  9. PharmatrophiX ($1M to $10M)
  10. vTv Therapeutics (Less than $1M)
  11. Viamet Pharmaceuticals ($1M to $10M)
  12. Marius Pharmaceuticals ($1M to $10M)
  13. Scioderm (Less than $1M)
  14. Dignify Therapeutics ($1M to $10M)
  15. Asklepios BioPharmaceutical ($10M to $50M)
  16. Praetego ($10M to $50M)
  17. SCYNEXIS (Less than $1M)
  18. Chimerix ($1M to $10M)
  19. ZY Therapeutics (Less than $1M)
  20. Troy Medicare ($1M to $10M)
  21. Physicians Own Pharmacy (Less than $1M)
  22. ScitoVation (Less than $1M)
  23. Chaperone Therapeutics ($10M to $50M)
  24. UNC Center for Aging and Health ($10M to $50M)
  25. BioKier (Less than $1M)
  26. Triangle Biotechnology ($1M to $10M)
  27. Liquidia Technologies ($10M to $50M)
  28. Adhera Therapeutics ($10M to $50M)
  29. Biologics ($100M to $500M)
  30. NeuroCog Trials ($1M to $10M)
  31. Synereca Pharmaceuticals ($1M to $10M)
  32. nContact Surgical (Less than $1M)
  33. Pneuma Respiratory (Less than $1M)
  34. Wright Avenue Partners (Less than $1M)
  35. Centice ($10M to $50M)
  36. SOV Therapeutics (Less than $1M)
  37. Arrivo BioVentures LLC ($1M to $10M)
  38. RENOVION ($1M to $10M)
  39. inSomaBio (Less than $1M)
  40. Chiesi USA, Inc. ($10M to $50M)
  41. Entegrion ($50M to $100M)
  42. Vast Therapeutics ($1M to $10M)
  43. Fennec Pharmaceuticals ($1M to $10M)
  44. Balanced Pharma ($10M to $50M)
  45. GeneBiology ($1M to $10M)
  46. TransEnterix ($1M to $10M)
  47. Innocrin Pharmaceuticals ($1M to $10M)
  48. QATCH Technologies ($1M to $10M)
  49. Inhalon Biopharma ($10M to $50M)
  50. Fervent Pharmaceuticals (Less than $1M)
  51. Gemelli Biotech ($1M to $10M)
  52. BioDelivery Sciences International ($50M to $100M)
  53. CoLucid Pharmaceuticals ($10M to $50M)
  54. BioMarck Pharmaceuticals (Less than $1M)
  55. Polarean ($1M to $10M)
  56. Cempra ($10M to $50M)
  57. FLAG Therapeutics (Less than $1M)
  58. Emergo Therapeutics ($1M to $10M)
  59. Corinthian Ophthalmic ($1M to $10M)
  60. TransTech Pharma ($10M to $50M)
  61. Continuous Precision Medicine (Less than $1M)
  62. SmartFlow Technologies (Less than $1M)
  63. Civatech Oncology ($1M to $10M)
  64. Sprout Pharmaceuticals ($1M to $10M)
  65. Agile Sciences (Less than $1M)
  66. PhosphoGam ($1M to $10M)
  67. Locus Biosciences ($1M to $10M)
  68. Cloud Pharmaceuticals ($10M to $50M)
  69. Lamassu Pharma (Less than $1M)
  70. DARA BioSciences ($1M to $10M)
  71. LQ3 Pharmaceuticals ($1M to $10M)
  72. Aerial BioPharma (Less than $1M)


  1. Salix Pharmaceuticals ($500M to $1B)

    Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders. For more than 20 years, they have licensed, developed, and marketed innovative products to treat GI problems. It's their mission to give healthcare providers and patients the most effective solutions in gastroenterology.

    • $500M to $1B annual revenues
    • 501-1000 employees
    • $750M raised in December, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. people having meeting on rectangular brown table


  3. Sisu Pharma ($1M to $10M)

    Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolonged treatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.7M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. man and woman sitting at table


  5. Arrevus (Less than $1M)

    Although there is a clear increase in bacteria “resistant” to standard therapies in a “test tube”, the real importance of resistance is when it becomes a clinical problem because of decreased effectiveness to treat serious life-threatening disease in patients by affecting clinical outcomes, such as mortality, decreased function and decreased quality of life for patients. For some diseases that are self-resolving and for which antibiotics aren’t required (e.g., sinusitis, bronchitis, otitis media, skin abscesses), identification of antibiotic resistance remains a test tube phenomenon with little impact on patient outcomes. More concerning illnesses, such as serious disease due to methicillin-resistant S. aureus (MRSA), resistance may indeed result in decreased effectiveness for some older drugs but many therapies still remain and many new therapies currently exist to treat MRSA. Arrevus is focusing its drug development efforts on those diseases for which antibiotic resistance has important clinical implications and for which few therapies exist. These efforts are dedicated to the development of Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (“DPCs”)

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.8M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  6. EternaTear (Less than $1M)

    EternaTear is developing a next-generation therapy for the over-the-counter dry eye market. Dry eye is the inability of the tear film and lids to protect the surface of the eye, resulting in itching, burning, and pain. With a dozen or more underlying causes, dry eye is notoriously difficult to diagnose and treat, and if left untreated, it can lead to permanent corneal damage. Patients with even moderate dry eye can suffer from debilitating symptoms that lead to a drastically reduced quality of life. Current treatment options are limited, and most patients rely on over-the-counter eye drops for temporary relief. But because they neither treat the root cause nor appropriately address the symptoms, current products on the market fail to provide adequate relief and must be reapplied as often as 6-12 times every day. By pairing proven technologies with pioneering research, EternaTear™ is developing a product that is closest to natural tears. Using a previously unrecognized mechanism, EternaTear™ can remain on the eye for an extended period of time, reducing the number of applications per day and giving Dry Eye patients lasting relief.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  7. group of people sitting beside rectangular wooden table with laptops


  8. Exodos Life Science Partners ($1M to $10M)

    Exodos Life Sciences Limited Partnership develops pharmaceutical products. Its projects include topical treatment for migraine and raynaud’s; non-steroidal anti-inflammatory drugs for mild to moderate pain; and cold sore topical therapeutics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.7M raised in March, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  9. people using desktop computer inside office


  10. NovaTarg Therapeutics (Less than $1M)

    NovaTarg Therapeutics is a privately owned pharmaceutical company that has a leadership team experienced in drug discovery which has established a novel approach to the discovery of tissue targeted medicines.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3.2M raised in September, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  11. people sitting on chairs near tables during daytime


  12. CertiRx ($10M to $50M)

    CertiRx Corporation develops and commercializes platform technology for authentication and verification of high-value products and important documents. Its products include AuthentiForm Document Security, a software solution for supply chain documents; CertiTag Manufactured Goods Authentication, a platform technology for authenticating products that are intended for ingestion, such as foods and pharmaceuticals; and TraxSecur Enhanced Track & Trace, a software solution for product packaging that tracks and traces information. It serves pharmaceuticals, agriculture and food, document security, electronic components, luxury goods, and manufacturing industries. The company was incorporated in 2011 and is based in Durham, North Carolina.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in May, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  13. rectangular brown wooden table with chair lot inside building


  14. Charter Medical (Less than $1M)

    Charter Medical, Ltd. is a subsidiary of Fenner PLC (LSE: FENR). They have a 25 year history of developing and providing specialty single-use products to the blood transfusion, cell therapy, biotechnology and pharmaceutical markets. Their 15,000 square feet of clean room space located in Winston-Salem, NC, USA is ISO 13485 certified and FDA registered. Focus is on designing and supplying single-use solutions for cell growth, frozen storage and biological fluid handling. Charter Medical is committed to providing quality products and services with and experienced staff dedicated to exceeding customer expectations from product development, delivery and implementation.

    • Less than $1M annual revenues
    • 51-100 employees
    • $1M raised in June, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  15. grey wooden table and black leather rolling chairs


  16. PharmatrophiX ($1M to $10M)

    San Francisco's PharmatrophiX, a biotech working on drugs that prevent neurodegenerative disease. Founded by Stanford researcher Frank Longo, PharmatrophiX is developing a class of drugs that mimic the activity of proteins called neurotrophins, which aid in the development, health and survival of neurons.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $10.3M raised in November, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  17. three women sitting around table using laptops


  18. vTv Therapeutics (Less than $1M)

    vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. vTv Therapeutics has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company. The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology. vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo. Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification. vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.

    • Less than $1M annual revenues
    • 251-500 employees
    • $2M raised in October, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  19. brown and white table and chairs


  20. Viamet Pharmaceuticals ($1M to $10M)

    Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $12M raised in September, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  21. photo of industrial machines near table


  22. Marius Pharmaceuticals ($1M to $10M)

    Marius Pharmaceuticals is a biopharmaceutical company that develops oral testosterone replacement therapy to bring novel treatments to a range of diseases with unmet medical needs. The company's solutions overcome many of the problems associated with currently approved products and their proprietary delivery technology has reached optimal absorption with all meal types resulting in a higher bioavailability, providing men suffering from low testosterone with a safe and efficacious treatment. The company was founded in 2017 and headquartered in Raleigh, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $5.6M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  23. brown wooden table and chairs


  24. Scioderm (Less than $1M)

    Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.

    • Less than $1M annual revenues
    • 11-50 employees
    • $20M raised in December, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  25. two women sitting beside table using MacBooks


  26. Dignify Therapeutics ($1M to $10M)

    Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations. By combining novel pharmaceutical agents with drug delivery technology, Dignify Therapeutics will redefine the treatment of these disorders and restore the dignity of voluntary excretory function for these patients. The company was founded in 2013 and is headquartered in Raleigh, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3.6M raised in March, 2019
    • 9 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  27. two men using computers


  28. Asklepios BioPharmaceutical ($10M to $50M)

    Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $2.7M raised in September, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  29. men using computers


  30. Praetego ($10M to $50M)

    Praetego is a pharmaceutical company focused on addressing serious diabetic complications. The company's novel and proprietary small molecule candidates target a common pathway in disease progression leading to serious complications. Praetego is headquartered in Durham, North Carolina.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.4M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  31. grayscale photo of people in room


  32. SCYNEXIS (Less than $1M)

    SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.

    • Less than $1M annual revenues
    • 51-100 employees
    • $35M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  33. people sitting in front of computer monitors


  34. Chimerix ($1M to $10M)

    Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $100M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  35. rolling armchair beside table


  36. ZY Therapeutics (Less than $1M)

    ZY Therapeutics develops a drug delivery platform for cancer therapeutics using nanotechnology.

    • Less than $1M annual revenues
    • 11-50 employees
    • $6M raised in June, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  37. people standiunmg


  38. Troy Medicare ($1M to $10M)

    Troy Medicare is an AI-driven, pharmacy-powered Medicare Advantage company. The company presents a Medicare advantage plan that uses data and technology, enabling people to get access to the fair, transparent, and personalized health plan as well as pharmacies and health care providers to truly impact each patient's health and get rewarded for those results. Troy Medicare was founded in 2018 and is headquartered in Charlotte, North Carolina.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $10M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  39. people sitting on black chairs


  40. Physicians Own Pharmacy (Less than $1M)

    Physicians' Own Pharmacy provides gloves, syringes, surgical instruments, and lab glassware. Founded by physicians in 2010, POP Medical began with a simple idea: To lower medical supply prices by eliminating unnecessary expenses. POP Medical is a resource for medical devices, supplies, and pharmaceuticals.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.5M raised in May, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  41. men sitting of chair inside room


  42. ScitoVation (Less than $1M)

    ScitoVation is a biotechnology company that provides technical expertise and technology on pharmaceuticals and agricultural chemicals. The company also helps clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. They develop customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data. ScitoVation investigates complex issues, such as chemical modes of action, animal to human exposure extrapolation, and the use of genetic expression and sequencing data to ascertain toxicity. It was founded in 2016 and is headquartered in Durham, North Carolina, USA.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  43. architectural photo of buildings during daytime


  44. Chaperone Therapeutics ($10M to $50M)

    Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding: the underlying causes of neurodegenerative and other rare diseases.Their therapeutic approaches elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death. Chaperone’s unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of protein misfolding disease and clinical evaluation propel their therapeutic discovery programs forward.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.5M raised in January, 2017
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  45. man in black jacket sitting on chair


  46. UNC Center for Aging and Health ($10M to $50M)

    They provide the highest quality of clinical care to older patients; connect families and caregivers with community resources; and train the next generation of Geriatricians. But they don’t stop there. Improving care for older adults means training different types of providers – including dentists, pharmacists, cardiologists, and oncologists – in best practices of geriatric medicine that are grounded in research, informed by patient priorities, and guided by compassion.

    • $10M to $50M annual revenues
    • 1001-5000 employees
    • $3.8M raised in August, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  47. man in gray sweatshirt sitting on chair in front of iMac


  48. BioKier (Less than $1M)

    BioKier is an early-stage pharmaceutical company that develops drugs for diabetes and related disorders. It offers oral pills for the treatment of type 2 diabetes, as well as for metabolic syndrome and obesity conditions. It was incorporated in 2008 and is based in Chapel Hill, North Carolina

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in January, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  49. selective focus photography of desk lamp on table


  50. Triangle Biotechnology ($1M to $10M)

    Triangle Biotechnology's mission to accelerate research by delivering revolutionary sample prep solutions. we bring you innovative, high-quality, high-throughput sonication solutions for biological sample preparation. We believe your research is too important to let a simple process like sample prep slow you down.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  51. tennis table in room


  52. Liquidia Technologies ($10M to $50M)

    Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $22.4M raised in December, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  53. people sitting and using laptops


  54. Adhera Therapeutics ($10M to $50M)

    Adhera Therapeutics is a specialty pharmaceutical company focused on patient-centric care for hypertension and pain. Adhera Therapeutics is headquartered in Durham, North Carolina.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $3.2M raised in June, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  55. rectangular brown wooden table


  56. Biologics ($100M to $500M)

    Biologics, Inc. is an oncology management services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities. Offering a holistic approach to oncology care, the company provides the following services: Care Integration, Oncology Pharmacy Services, Patient Access Services, Strategic Market Solutions and Clinical Research Services. Biologics was founded in 1994 and maintains headquarters and operations in Cary, North Carolina.

    • $100M to $500M annual revenues
    • 251-500 employees
    • $29M raised in April, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  57. people sitting beside rectangular brown table with laptops


  58. NeuroCog Trials ($1M to $10M)

    NeuroCog Trials (NCT) is a cognition and clinical assessment services company devoted exclusively to applying rigorous standards for key endpoints in multi-site clinical trials. Founded in 2005, NeuroCog Trials is a privately held, certified woman-owned business, headquartered in Durham, North Carolina. There are currently 110 Durham based and 50+ international employees and local language experts.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $1.4M raised in May, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  59. Synereca Pharmaceuticals ($1M to $10M)

    Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-positive and gram-negative pathogens through various bactericidal antibiotics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.6M raised in August, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. people having meeting on rectangular brown table


  61. nContact Surgical (Less than $1M)

    nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

    • Less than $1M annual revenues
    • 11-50 employees
    • $20M raised in November, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. man and woman sitting at table


  63. Pneuma Respiratory (Less than $1M)

    Pneuma Respiratory is a pharmaceutical company that creates digital solutions for respiratory drug delivery. It has created PNEUMAHALER, the first fully integrated digital breath activated inhaler. The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health care providers. Using Pneuma's digital droplet ejector technology, Pneuma's device, although currently available for investigational purposes only, has the potential to ultimately deliver a spectrum of novel therapies, including biologics, through the lungs. Pneuma Respiratory was founded in 2015 and is headquartered in Boone, North Carolina, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  64. Wright Avenue Partners (Less than $1M)

    Wright Avenue Partners was recently founded by a team of experienced industry leaders who want to improve the clinical development process the "Wright" way. We tailor our Functional Service Provider and resourcing solutions to your needs by partnering you with highly experienced consultants to help keep your clinical program on track. We'll guide you through the entire process and determining all the variables involved in selecting, managing and contracting the resources you need to keep your projects on schedule with the proper clinical skills.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.8M raised in July, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  65. group of people sitting beside rectangular wooden table with laptops


  66. Centice ($10M to $50M)

    Centice develops PASS Rx, a pharmaceutical authentication sensor system improving the verification process for dispensed medications. Centice has focuses on the development of the PASS Rx system, a pharmaceutical verification product. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.5M raised in January, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  67. people using desktop computer inside office


  68. SOV Therapeutics (Less than $1M)

    SOV Therapeutics, Inc. is as a clinical stage biotechnology company that focuses on development of oral testosterone replacement therapies for adult men. The company’s oral T-replacement therapy uses testosterone undecanoate, a pro-drug of testosterone, to formulate and deliver oral testosterone for therapeutic treatment. SOV Therapeutics, Inc. is based in Morrisville, North Carolina.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in November, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  69. people sitting on chairs near tables during daytime


  70. Arrivo BioVentures LLC ($1M to $10M)

    Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and other regulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $49M raised in May, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  71. rectangular brown wooden table with chair lot inside building


  72. RENOVION ($1M to $10M)

    Renovion company is a pharmaceutical corporation with therapy for chronic inflammatory airway diseases. The company’s flagship pharmaceutical product, Arina-1, is still in pre-clinical stages.Renovation was formed in 2013 to leverage a pharmaceutical discovery at the University of North Carolina-Chapel Hill that reduces infection and addresses airway inflammation through the use of a novel therapy – Arina-1.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $8.1M raised in June, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  73. grey wooden table and black leather rolling chairs


  74. inSomaBio (Less than $1M)

    inSomaBio is a biotechnology company based in Durham, North Carolina.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  75. three women sitting around table using laptops


  76. Chiesi USA, Inc. ($10M to $50M)

    Chiesi USA is a pharmaceuticals company specializing in pharmaceutical research & development services.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $0.1M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  77. brown and white table and chairs


  78. Entegrion ($50M to $100M)

    Entegrion is a life sciences company dedicated to providing innovative solutions. Their products bring about major changes to the critical pathways in the diagnosis and treatment of patient coagulopathies, enabling clinicians to rapidly and effectively advance care in both the hospital and field environments. They partner with leading scientists, clinicians, and industry specialists to provide products that enable doctors to improve clinical outcomes for patients whose hemostatic state may be compromised.

    • $50M to $100M annual revenues
    • 11-50 employees
    • $4.2M raised in October, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  79. photo of industrial machines near table


  80. Vast Therapeutics ($1M to $10M)

    Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens present in cystic fibrosis and other respiratory disease patients. The company is in the preclinical stage of developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $15M raised in January, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  81. brown wooden table and chairs


  82. Fennec Pharmaceuticals ($1M to $10M)

    Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $7.6M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  83. two women sitting beside table using MacBooks


  84. Balanced Pharma ($10M to $50M)

    Balanced Pharma is a medical and dental pharmaceutical company that develops and manufactures local anesthetic drugs and devices that contribute to patient comfort and safety. The company maintains a team of individuals and organizations that enable the development and commercialization of the Libracaine product line. Balanced Pharma is located in Cornelius, North Carolina, and was founded by John Scott Keadle.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.5M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  85. two men using computers


  86. GeneBiology ($1M to $10M)

    GeneBiology develops a patented new drug for serious diseases using the 505(b)(2) regulatory pathway. The 505(b)(2) pathway is the fastest, least expensive, and lowest risk regulatory pathway for the development of important new drugs, because both data on file for prior approval(s) and published data can be used to fulfill regulatory requirements for both clinical development and commercial approval, thereby substantially reducing the costs (in time and money) and the risks of developing new drugs. They combine deep expertise in medicine, drug development, and formulation chemistry to identify, develop, and market patented new formulations/new routes of administration/new indications for approved medicines. GeneBiology is a privately funded corporation that began operations in 2006 and intends to remain private.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.4M raised in August, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  87. men using computers


  88. TransEnterix ($1M to $10M)

    TransEnterix, Inc. operates as a medical-device company which develops minimally invasive laparoscopic surgery platform. Its platform allows a surgeon to remove a patient's gall bladder and perform other abdominal surgeries without a scar. The company was founded in 2006 and is based in Durham, North Carolina. In 2013, SafeStitch Medical completed a reverse merger with TransEnterix, Inc., and the combined company was renamed TransEnterix.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $79.6M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  89. grayscale photo of people in room


  90. Innocrin Pharmaceuticals ($1M to $10M)

    Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer. The company offers CYP17 lyase, a validated enzyme target for the treatment of CRPC and other hormonally-driven conditions, such as breast cancer, endometriosis, or congenital adrenal hyperlplasia. Its product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth–androgen biosynthesis and AR transcriptional signaling.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $28M raised in April, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  91. people sitting in front of computer monitors


  92. QATCH Technologies ($1M to $10M)

    QATCH Technologies company that’s developing a tool to determine the injectability and manufacturability of biopharmaceutical products. Its proprietary technology can determine if a formulation is injectable or if there will be viscosity related manufacturing problems at very early stages.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  93. rolling armchair beside table


  94. Inhalon Biopharma ($10M to $50M)

    Inhalon Biopharma is into developing monoclonal antibodies (mAb) using technology that enables trapping of pathogens in mucus secretions for treating diseases of the respiratory tract.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.9M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  95. people standiunmg


  96. Fervent Pharmaceuticals (Less than $1M)

    Fervent Pharmaceuticals, LLC is a drug development company founded in 2011 focused on developing a treatment for an un-met medical need in women’s health, vasomotor symptoms commonly known as hot flashes, night sweats and insomnia.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in May, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  97. people sitting on black chairs


  98. Gemelli Biotech ($1M to $10M)

    Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics. It strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. The company is driven by its mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way. The company was founded in 2018 and headquartered in North Carolina, United States.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.9M raised in July, 2019
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  99. men sitting of chair inside room


  100. BioDelivery Sciences International ($50M to $100M)

    BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

    • $50M to $100M annual revenues
    • 101-250 employees
    • $60M raised in May, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  101. architectural photo of buildings during daytime


  102. CoLucid Pharmaceuticals ($10M to $50M)

    CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $37.1M raised in January, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  103. man in black jacket sitting on chair


  104. BioMarck Pharmaceuticals (Less than $1M)

    BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and a Phase 2 study of the efficacy of BIO-11006 in COPD patients. Data from the Phase 2 study demonstrated proof-of-concept of BIO-11006. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology, and his co-workers.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.8M raised in February, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  105. man in gray sweatshirt sitting on chair in front of iMac


  106. Polarean ($1M to $10M)

    Polarean designs and manufactures equipment for the production of hyperpolarized xenon or helium gas. When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Current investigational uses include identifying early diagnoses of respiratory diseases as well as monitoring progression and therapeutic response. In addition, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs. The company is pursuing regulatory approval for clinical use and also sells its hyperpolarizes and related equipment to academic research institutions worldwide. In addition to providing academic researchers with this equipment and support, Polarean Imaging plc. offers access to the intellectual property that provides freedom-to-operate in this technology area. Polarean was founded in 2011 and is headquartered in Durham, NC, USA.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.9M raised in August, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  107. selective focus photography of desk lamp on table


  108. Cempra ($10M to $50M)

    Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $25.1M raised in October, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  109. tennis table in room


  110. FLAG Therapeutics (Less than $1M)

    FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms--the Anti-angiogenic/Anti-tubulin (AA/AT) platform and Folate-target Anti-cancer (FTAC) platform.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.3M raised in January, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  111. people sitting and using laptops


  112. Emergo Therapeutics ($1M to $10M)

    Emergo Therapeutics is a pharmaceutical startup that develops treatment options for flu-like illnesses. It is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases. Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells. Emergo is headquartered in Durham, North Carolina.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3.5M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  113. rectangular brown wooden table


  114. Corinthian Ophthalmic ($1M to $10M)

    Corinthian Ophthalmic, Inc. manufactures and markets drug delivery devices. The company was founded in 2010 and is based in Raleigh, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.6M raised in March, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  115. people sitting beside rectangular brown table with laptops


  116. TransTech Pharma ($10M to $50M)

    TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $50M raised in June, 2010
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  117. Continuous Precision Medicine (Less than $1M)

    They are engineering tools and services to combat one of the most costly and emotionally damaging issues in healthcare, opioid addiction.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.8M raised in September, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. people having meeting on rectangular brown table


  119. SmartFlow Technologies (Less than $1M)

    Separation performance expectations within the biopharmaceutical processing community have yielded exciting new breakthrough technologies that allow today's bioprocessing professionals to maximize yield and press for greater standards of purity and efficiency. SmartFlow Technologies, Inc. has extensive experience providing innovative filter modules, separation and purification solutions to enable companies throughout the world to better meet these new bioprocessing and manufacturing needs.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.8M raised in August, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. man and woman sitting at table


  121. Civatech Oncology ($1M to $10M)

    Civatech Oncology is a medical device company that develops polymer-based devices to treat cancer using localized low-dose-rate radiation. Because polymers are easy to manufacture in different shapes and formats, CivaTech's patented and patent-pending technology enables devices that can be designed and fabricated for specific tumor types. Its first product, the CivaString, has been granted FDA 510k clearance to treat any solid tumor.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.1M raised in December, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  122. Sprout Pharmaceuticals ($1M to $10M)

    Sprout Pharmaceuticals develops products for the treatment of female sexual dysfunction. They're committed to breakthrough firsts in women’s sexual health. The company was incorporated in 2011 and is based in Raleigh, North Carolina.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $20M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  123. group of people sitting beside rectangular wooden table with laptops


  124. Agile Sciences (Less than $1M)

    Agile Sciences is a biotechnology company that provides commercial solutions to the biopharma industry. The company is driven by its mission is to provide commercial solutions to those industries plagued by antibiotic resistance and biofilms. Internal R&D efforts at the Company are focused on pharmaceutical applications of the technology. It was founded in 2007 and headquartered in Raleigh, North Carolina.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  125. people using desktop computer inside office


  126. PhosphoGam ($1M to $10M)

    The Council for Entrepreneurial Development (CED) connects entrepreneurial companies with high-value resources to accelerate business growth.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.3M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  127. people sitting on chairs near tables during daytime


  128. Locus Biosciences ($1M to $10M)

    Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.1M raised in August, 2020
    • 6 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  129. rectangular brown wooden table with chair lot inside building


  130. Cloud Pharmaceuticals ($10M to $50M)

    Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. We use a proprietary design process that combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs that are well-qualified for development from the outset and have original composition of matter IP. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. Our approach amplifies the power of cloud computing and AI to radically improve drug discovery and design. We partner at all stages of drug development – from discovery through the clinic – and are building an extensive product pipeline that spans a wide range of indications.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.4M raised in February, 2016
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  131. grey wooden table and black leather rolling chairs


  132. Lamassu Pharma (Less than $1M)

    Lamassu Pharma is a biotech startup that solves the critical unmet medical need for severe acute pancreatitis. Their lead candidate is a novel small molecule therapy for acute pancreatitis. This was developed at Mayo Clinic by leading scientists and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. We are currently focused on the continued development of this compound through safety testing in preparation for definitive clinical trials. Our ultimate goal is to save the lives of patients afflicted with this disease.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.7M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  133. three women sitting around table using laptops


  134. DARA BioSciences ($1M to $10M)

    DARA is a specialty pharmaceutical company dedicated to the commercialization of oncology treatment and oncology supportive care products.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6M raised in February, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  135. brown and white table and chairs


  136. LQ3 Pharmaceuticals ($1M to $10M)

    LQ3 Pharmaceuticals, Inc. operates in the healthcare industry focusing on the pharmaceutical business. The company was incorporated in 2013 and is based in Morrisville, North Carolina.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $10M raised in September, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  137. photo of industrial machines near table


  138. Aerial BioPharma (Less than $1M)

    Aerial BioPharma is a privately-held biopharmaceutical company focused on developing biologics and small molecules for conditions in the Central Nervous System. Aerial is based in Morrisville, N.C., on the edge of Research Triangle Park.

    • Less than $1M annual revenues
    • 1-10 employees
    • $9.5M raised in February, 2013
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  139. brown wooden table and chairs